E. Max Laminate Veneers With and Without Using Galla Chinnesis as Natural Cross Linking and Remineralizing Agent
Launched by CAIRO UNIVERSITY · Dec 13, 2016
Trial Information
Current as of May 30, 2025
Unknown status
Keywords
ClinConnect Summary
one year Clinical evaluation of laminate veneers with amelogenesis imperfecta Will application of galla chinensis before Bonding of laminate veneers with adhesive resin cement provide better survival rate than conventional Bonding method
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- All subjects are required to be:
- • From 18-60 years old, and able to read and sign the informed consent document.
- • Physically and psychologically able to tolerate conventional restorative procedures
- • Have no active periodontal or pulpal diseases, have teeth with good restorations
- • Patients with teeth problems indicated for laminate veneer (e.g. discoloration, fracture not involve more than 50% enamel loss, mild malposition, ....)
- • Willing to return for follow-up examinations and evaluation
- Exclusion Criteria:
- • Patients in the growth stage with partially erupted teeth
- • Patient with fractured teeth of more than 50% enamel loss
- • Patients with poor oral hygiene and motivation
- • Pregnant women
- • Psychiatric problems or unrealistic expectations
- • Lack of opposite occluding dentition in the area intended for restoration
About Cairo University
Cairo University, a premier institution in Egypt, is dedicated to advancing medical research and education through innovative clinical trials. With a strong emphasis on improving healthcare outcomes, the university collaborates with various stakeholders to conduct rigorous scientific studies that address critical health challenges. Leveraging its extensive resources and expert faculty, Cairo University aims to contribute valuable insights to the medical community and enhance patient care both locally and globally. Through its commitment to ethical research practices and excellence, the university plays a pivotal role in shaping the future of healthcare in the region.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Patients applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials